Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
BMJ Case Rep ; 17(1)2024 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-38176750

RESUMO

IgM monoclonal gammopathies such as IgM myeloma and Waldenström macroglobulinaemia are distinct haematological conditions; however, differentiating between these entities can often present as a challenge.In this review, we explore the challenging diagnosis and treatment of IgM myeloma in a patient presenting with unexplained macrocytic anaemia, elevated serum protein and IgM levels in the absence of t(11;14) and lytic bone lesions that are classically associated with the diagnosis of IgM myeloma. The diagnosis was established based on 40% monoclonal plasma cell population on a bone marrow biopsy, gain of 1q21 on fluorescence in situ hybridisation, cyclin D1 positivity and absence of MYD88 mutation.


Assuntos
Mieloma Múltiplo , Macroglobulinemia de Waldenstrom , Humanos , Mieloma Múltiplo/patologia , Medula Óssea/patologia , Plasmócitos/patologia , Macroglobulinemia de Waldenstrom/genética , Imunoglobulina M
2.
Immunotherapy ; 11(18): 1533-1540, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31815569

RESUMO

Immunotherapy drugs are associated with a multitude of immune-related adverse events. We describe a case of cardiac tamponade in a patient with stage IV lung adenocarcinoma, with almost 100% expression of PDL-1, treated with pembrolizumab. The patient is a 62-year-old male who developed worsening shortness of breath after five cycles of pembrolizumab. He was diagnosed with large pericardial effusion on computed tomography chest. Echocardiogram confirmed tamponade physiology. He was treated with discontinuation of pembrolizumab and urgent pericardial window followed by high dose prednisone with tapering. The patient responded very well to the treatment. We have comprehensively reviewed cases of pericardial effusion secondary to either immune mediated mechanisms or pseudoprogression.


Assuntos
Adenocarcinoma de Pulmão/terapia , Anticorpos Monoclonais Humanizados/efeitos adversos , Antineoplásicos Imunológicos/efeitos adversos , Tamponamento Cardíaco/induzido quimicamente , Neoplasias Pulmonares/terapia , Adenocarcinoma de Pulmão/patologia , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais Humanizados/administração & dosagem , Antineoplásicos Imunológicos/administração & dosagem , Tamponamento Cardíaco/tratamento farmacológico , Tamponamento Cardíaco/patologia , Tamponamento Cardíaco/fisiopatologia , Cardiotoxicidade/tratamento farmacológico , Cardiotoxicidade/patologia , Cardiotoxicidade/fisiopatologia , Humanos , Imunoterapia/efeitos adversos , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Derrame Pericárdico/induzido quimicamente , Derrame Pericárdico/tratamento farmacológico , Derrame Pericárdico/patologia , Derrame Pericárdico/fisiopatologia , Prednisona/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA